The Promise of Predictive Biomarkers for Antipsychotic Efficacy: A Review of Peripheral microRNAs to Evaluate Schizophrenia Treatment Response

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.
2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. PubMed CrossRef
3. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76. PubMed CrossRef
4. NIMH ” Schizophrenia. National Institute of Mental Health Information Resource Center website. Accessed February 9, 2022. https://www.nimh.nih.gov/health/statistics/schizophrenia
5. Multani PK, Saini N, Kaur R, et al. Biomarkers for Drugs of Abuse and Neuropsychiatric Disorders: Models and Mechanisms. In: Gupta RC, ed. Biomarkers in Toxicology. Academic Press; 2014:983–1001.
6. Wakefield JC. Misdiagnosing normality: psychiatry’s failure to address the problem of false positive diagnoses of mental disorder in a changing professional environment. J Ment Health. 2010;19(4):337–351. PubMed CrossRef
7. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17(12):1174–1179. PubMed CrossRef
8. Vargas G. Biomarkers in schizophrenia. Biomarkers Med. 2014;8(1):1–3. PubMed CrossRef
9. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5(6):463–466. PubMed CrossRef
10. Yu HC, Wu J, Zhang HX, et al. Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2015;63:23–29. PubMed CrossRef
11. Shi W, Du J, Qi Y, et al. Aberrant expression of serum miRNAs in schizophrenia. J Psychiatr Res. 2012;46(2):198–204. PubMed CrossRef
12. Liu S, Yuan YB, Guan LL, et al. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission. Chin Med J (Engl). 2013;126(14):2676–2680. PubMed
13. Song HT, Sun XY, Zhang L, et al. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. J Psychiatr Res. 2014;54:134–140. PubMed CrossRef
14. Sun XY, Zhang J, Niu W, et al. A preliminary analysis of microRNA as potential clinical biomarker for schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2015;168(3):170–178. PubMed CrossRef
15. Wei H, Yuan Y, Liu S, et al. Detection of circulating miRNA levels in schizophrenia. Am J Psychiatry. 2015;172(11):1141–1147. PubMed CrossRef
16. Chen SD, Sun XY, Niu W, et al. A preliminary analysis of microRNA-21 expression alteration after antipsychotic treatment in patients with schizophrenia. Psychiatry Res. 2016;244:324–332. PubMed CrossRef
17. Liu S, Zhang F, Shugart YY, et al. The early growth response protein 1-miR-30a-5p-neurogenic differentiation factor 1 axis as a novel biomarker for schizophrenia diagnosis and treatment monitoring. Transl Psychiatry. 2017;7(1):e998. PubMed CrossRef
18. Jin XF, Wu N, Wang L, et al. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601–613. PubMed CrossRef
19. Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47(D1):D155–D162. PubMed CrossRef
20. Wahid F, Shehzad A, Khan T, et al. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803(11):1231–1243. PubMed CrossRef
21. Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–561. PubMed CrossRef
22. Cai Y, Yu X, Hu S, et al. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 2009;7(4):147–154. PubMed CrossRef
23. Caputo V, Ciolfi A, Macri S, et al. The emerging role of MicroRNA in schizophrenia. CNS Neurol Disord Drug Targets. 2015;14(2):208–221. PubMed CrossRef
24. Beveridge NJ, Cairns MJ. MicroRNA dysregulation in schizophrenia. Neurobiol Dis. 2012;46(2):263–271. PubMed CrossRef
25. Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008;17(8):1156–1168. PubMed CrossRef
26. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006. PubMed CrossRef
27. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–10518. PubMed CrossRef
28. Kichukova TM, Popov NT, Ivanov HY, et al. Circulating microRNAs as a novel class of potential diagnostic biomarkers in neuropsychiatric disorders. Folia Med (Plovdiv). 2015;57(3-4):159–172. PubMed CrossRef
29. Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40(6):407–414. PubMed CrossRef
30. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303–318. PubMed CrossRef
31. Gardiner E, Beveridge NJ, Wu JQ, et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry. 2012;17(8):827–840. PubMed CrossRef
32. Miller BH, Zeier Z, Xi L, et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci U S A. 2012;109(8):3125–3130. PubMed CrossRef